IN THE COURT OF APPEAL OF NEW ZEALAND
CA165/03
CA206/03BETWEENHELA PHARMA AB
Appellant
ANDHELA PHARMA AUSTRALASIA LIMITED
Respondent
Hearing:1 February 2005
Court:McGrath, Glazebrook and Hammond JJ
Counsel:J R F Fardell QC and T P Mullins for Appellant
P D McKenzie QC for Respondent
Judgment:17 February 2005
JUDGMENT OF THE COURT
A The appeals are dismissed.
BThe appellant is to pay costs of $7,500 to the respondent together with the reasonable disbursements of the respondent on the appeals. In the event that the parties are unable to settle the disbursements, same are to be fixed by the Registrar.
REASONS
(Given by Hammond J)
Table of Contents
PARA NO INTRODUCTION [1] THE FACTS [3] WAS THE ARBITRATION DISPLACED? [28] THE INTERIM AWARD [33] THE APPEAL AND APPLICATION TO THE HIGH COURT [39] THE HIGH COURT DECISION [42] THE SUBMISSIONS IN THIS COURT [52] THE RELEVANT LEGAL PRINCIPLES [54] THIS CASE [61] CONCLUSION [71] INTRODUCTION
[1] We have before us appeals from a single judgment of Goddard J in CIV‑2002-485-201 and CIV-2002-485-1377 Wellington Registry delivered on 1 August 2003. The same issues arose in both matters. Essentially, the Judge declined to interfere with the decision of an arbitrator as to who the proper parties to the reference to arbitration before him are.
[2] The central facts of the matters which have come before us are not now in dispute. What is in dispute, is the proper characterisation of the relationship (if any) between the parties, at the relevant times. In the result, we take essentially the same view of those issues as were taken by the arbitrator - and in more extended form - by Goddard J on the appeals to the High Court. Those issues can only be appreciated in the particular factual context of this case, to which we now turn.
The facts
[3] Hela i Falkoping AB (“HF”) was a Swedish company. It was the product licence-holder of a herpes cream called “Herstat”, and certain other products. We use the past tense with respect to “HF” for reasons we will come to later in this judgment.
[4] HF wished to establish a distributor for these products in New Zealand, Australia, the South Pacific and Indonesia. Hela Pharma Australasia Limited (“HAPL”), a New Zealand company, wished to become that distributor.
[5] On 10 June 1996 HF entered into an agreement with HPAL and another in Norway (International Business Developments AS) to effect this enterprise.
[6] The distribution agreement was signed by Mr Per Rabe (who was the president of HF) for that company, and by appropriate representatives of the other parties.
[7] Broadly, HPAL was given the sole and exclusive right to distribute HF’s products in New Zealand, Australia, the South Pacific and Indonesia. It was also given the first option to distribute the products in certain other Asian countries.
[8] The agreement provided for HF to terminate the agreement on six months written notice; and for either party to the agreement to terminate it without notice if the other…
Keep reading for free
Create a free CaseChat account to read Hela Pharma AB v Hela Pharma Australasia Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2005] NZCA 11
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.